Pfizer made one thing clear this week: It's officially back in the obesity race.

Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Eli Lilly’s Zepbound is still viewed as the leading weight-loss shot, according to a ...

Studies show that women who use a contraceptive injection known as Depo-Provera could increase their risk of benign brain tumours by as much as 500 per cent.

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a placebo.

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from Metsera. The company outlined plans to launch an expansive late stage ...

Pfizer Inc. (NYSE:PFE) is one of the best medical research stocks to buy according to hedge funds. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted ...

Pfizer (PFE) stock is in focus as the firm gets FDA priority review for its marketing application seeking a label expansion ...

In 2025, Pfizer PFE upped its efforts to rebuild its pipeline through acquisitions. Pfizer invested around $9 billion in M&A ...